Tenaya Therapeutics Doses First Patient in RIDGE(TM)-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Stock Information for Tenaya Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tenaya Therapeutics Inc.

Tenaya Therapeutics Announces Pricing of Public Offering
Tenaya Therapeutics Announces Proposed Public Offering
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE(TM)-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1(TM) Phase 1b/2a Clinical Trial of TN-201 Gene Therapy
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK(TM)-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.